A single injection into the inner ear restored functional hearing in 90% of people born deaf because of mutations in the OTOF gene, according to results from a clinical trial published in Nature in early 2026. The study followed 42 participants across eight medical centers for up to 2.5 years, making it the largest and longest-running trial of gene therapy for inherited deafness reported to date.
The participants ranged from infants as young as 10 months to adults older than 32. All carried mutations causing DFNB9, a condition in which the protein otoferlin fails to work properly, severing the connection between the inner ear’s hair cells and the auditory nerve. Without that protein, sound reaches the ear but never becomes a signal the brain can interpret. Until now, cochlear implants were the primary option for these patients.
What the trial showed
Surgeons delivered an adeno-associated virus vector called AAV1-hOTOF through the round window membrane of the cochlea using an endoscopic technique. The vector carried a functional copy of the OTOF gene, essentially giving hair cells the instructions they had always lacked to produce otoferlin.
Across the full cohort, 90% of treated individuals recovered measurable hearing. Auditory brainstem response (ABR) testing and behavioral audiometry confirmed that improvements were sustained over the entire follow-up period, not just in the weeks after surgery. For families affected by DFNB9, that durability matters: it suggests the therapy is not a temporary fix but a lasting change in how the ear functions.
The surgical approach built on earlier work that tested bilateral AAV1-hOTOF delivery in children with DFNB9. That prior study, which detailed the endoscopic round-window procedure and vector preparation protocols, established a safety and feasibility framework that gave researchers confidence to expand into a larger, multicentre trial with a broader age range.
Before any human received the therapy, preclinical work in nonhuman primates showed that AAV-based otoferlin delivery could reach cochlear hair cells without widespread off-target effects. A toxicology and biodistribution analysis from those animal studies provided the dose-ranging data that informed the first-in-human dosing decisions.
How it compares to other programs
The 90% response rate stands in contrast to a separate gene therapy called DB-OTO, developed under the CHORD Study Group. In that Phase 1/2 trial, hearing sensitivity was normalized in 3 of 12 patients, based on published interim results and data presented at the American Society of Gene and Cell Therapy meeting. One child in the CHORD study achieved normal hearing within 24 weeks; another showed early improvement at six weeks.
Those are meaningful results for individual families, but the gap between the two programs raises questions. The trials differ in vector design, promoter choice, dosing strategy, delivery method, and patient selection, so a direct head-to-head comparison is not possible. What the two programs collectively demonstrate is that replacing otoferlin can restore hearing in humans. The open question is which combination of design choices produces the strongest, most consistent outcomes.
A third clinical program using AAVAnc80-hOTOF, historically associated with Akouos and Eli Lilly, is also registered as an active trial, further broadening the pipeline of potential treatments for OTOF-related deafness.
What remains uncertain
Two and a half years is the longest follow-up reported so far, but it is a fraction of a lifetime. AAV vectors generally do not integrate into the host genome, and researchers do not yet know how long otoferlin expression will persist in human hair cells. Those cells are relatively long-lived, but they remain vulnerable to aging, noise exposure, and infection. No data beyond the 2.5-year mark exist, so any predictions about lifelong durability are speculative.
The trial’s single-arm design, with no placebo or sham-surgery control group, also limits the strength of its conclusions. A 90% recovery rate is striking, but without randomization and blinding, the results cannot fully rule out confounding factors such as spontaneous improvement in very young children or variations in testing methods across centers. Regulators will likely require larger, controlled studies before weighing approval.
Age is another variable that has not been fully parsed. Younger patients tend to have more adaptable auditory pathways and less cortical reorganization from years of silence, potentially making them more responsive to restored cochlear input. Adults who have relied on visual communication for decades may experience different functional outcomes even if their ABR thresholds improve on paper. The published data have not yet broken down results by age subgroup in enough detail to identify an optimal treatment window.
Practical questions loom as well. AAV-based gene therapies are complex biologic products requiring specialized manufacturing facilities, strict quality controls, and careful cold-chain logistics. No official statement from trial sponsors or regulatory agencies addresses when AAV1-hOTOF might become available outside of clinical trials, what a single treatment might cost, or how access would be managed across different health systems. The socioeconomic and ethnic diversity of the 42-person cohort has not been detailed, making it difficult to assess how broadly the results apply across populations with different genetic backgrounds and levels of healthcare access.
What this means for families affected by OTOF deafness
DFNB9 accounts for roughly 2% to 8% of congenital hearing loss cases, depending on the population studied. In absolute numbers, that translates to thousands of children born each year worldwide who could potentially benefit from otoferlin gene therapy if it reaches clinical use. For those families, the current evidence supports cautious optimism.
The AAV1-hOTOF trial demonstrates that a single inner-ear injection can produce clinically meaningful hearing recovery in a large majority of treated individuals, backed by objective measurements sustained over at least 2.5 years. At the same time, important unknowns remain: lifetime durability, the best age to intervene, how different gene therapy platforms compare, and the cost and logistics of delivering a one-time biologic treatment to patients around the world.
In the hierarchy of clinical evidence, this is a well-conducted, peer-reviewed, single-arm trial. It sits above case reports and conference abstracts but below randomized controlled trials. The 90% figure should be understood as a carefully documented observation from a defined group of patients under specific surgical conditions, not as a guaranteed outcome for every person with OTOF mutations. Larger controlled trials and longer follow-up will determine whether these results hold up as the therapy moves toward potential regulatory review in the years ahead.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
